Compare AbCellera Biologics Inc (ABCL) vs Canadian Natural Resources Ltd. (CNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Canadian Natural Resources Ltd. — how do they compare? AbCellera Biologics Inc trades at $9.95 (market cap $2.99B), while Canadian Natural Resources Ltd. trades at $47.7 (market cap $98.11B). The key difference: Canadian Natural Resources Ltd. is far larger — about 32.8× AbCellera Biologics Inc's market cap, and Canadian Natural Resources Ltd. pays a 3.73% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | CNQ | |
|---|---|---|
Market Cap | $2.99B | $98.11B |
Sector | Health | Energy |
52-Week High | $9.76 | $50.55 |
52-Week Low | $2.78 | $29.31 |
Enterprise Value | $2.58B | $108.54B |
Dividend Yield | — | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
CNQ trades at $47.25, up 3.82% in 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.53, exceeding expectations, and maintains robust profitability with a net income margin of 22.87%. Recent news highlights record production and a quarterly dividend of $0.63, reinforcing financial strength.
Outlook is positive due to low valuation multiples, consistent dividend payouts, and upward earnings revisions. Key risks include oil price volatility and rising debt levels. Analyst consensus is strongly bullish with 75% buy ratings, supporting potential upside if operational momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →
